These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 17989600

  • 1. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
    Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G.
    Transplantation; 2007 Oct 27; 84(8):956-64. PubMed ID: 17989600
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 4. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L, Ding T, Wang XX, Lin ZB, Chen G.
    Zhonghua Yi Xue Za Zhi; 2016 May 31; 96(20):1556-61. PubMed ID: 27266681
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S, Sarafnejad A, Ahmadpoor P, Nafar M, Karimi M, Eteghadi A, Yekaninejad MS, Amirzargar AA.
    Hum Immunol; 2019 Sep 31; 80(9):739-747. PubMed ID: 30597187
    [Abstract] [Full Text] [Related]

  • 6. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ.
    Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558
    [Abstract] [Full Text] [Related]

  • 7. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB.
    Transplantation; 2007 May 27; 83(10):1324-9. PubMed ID: 17519781
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E, Cho YW, Hayashi R, Bunnapradist S.
    Transplantation; 2007 Oct 15; 84(7):821-8. PubMed ID: 17984833
    [Abstract] [Full Text] [Related]

  • 9. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 15; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 10. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 11. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N.
    Transplantation; 2010 Jun 27; 89(12):1511-7. PubMed ID: 20386144
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus vs cyclosporine after induction with basiliximab does not promote regulatory T cell expansion in de novo kidney transplantation: Results from a single-center randomized trial.
    Libetta C, Esposito P, Gregorini M, Margiotta E, Martinelli C, Borettaz I, Canevari M, Rampino T, Ticozzelli E, Abelli M, Meloni F, Dal Canton A.
    Transpl Immunol; 2015 Oct 27; 33(2):117-24. PubMed ID: 26220254
    [Abstract] [Full Text] [Related]

  • 13. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 14. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 15. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
    Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G.
    J Am Soc Nephrol; 2007 Mar 15; 18(3):1007-18. PubMed ID: 17287424
    [Abstract] [Full Text] [Related]

  • 16. Conversion from cyclosporine to sirolimus in stable renal transplant recipients.
    Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA.
    Transplantation; 2005 Dec 15; 80(11):1578-85. PubMed ID: 16371929
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.
    Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J, Bono MR, Fierro A, Iñiguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguiló J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E.
    Transplant Proc; 2008 Nov 15; 40(9):3223-8. PubMed ID: 19010240
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
    Sumethkul V, Changsirikulchai S, Lothuvachai T, Chalermsanyakorn P.
    Transplant Proc; 2006 Dec 15; 38(10):3470-2. PubMed ID: 17175307
    [Abstract] [Full Text] [Related]

  • 20. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J.
    Transplantation; 2004 Jan 27; 77(2):244-51. PubMed ID: 14742989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.